---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103543"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:18:17.669883+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantheus Q2 rev $378M, adj EPS $1.57; cuts FY25 guidance; FDA NDA acceptance; $400M buyback

## Summary
- Q2 revenue $378.0M (-4.1% YoY); GAAP EPS $1.12; adjusted EPS $1.57.
- PYLARIFY sales $250.6M (-8.3%); DEFINITY sales $83.9M (+7.5%).
- FY25 revenue guidance cut to $1.475-$1.51B from $1.55-$1.585B; adj EPS to $5.50-$5.70 from $6.60-$6.70.
- FDA accepted NDA for new piflufolastat F 18 formulation; PDUFA date March 6, 2026; batch size +~50%.
- Board authorized $400M share repurchase program through Dec 2027, replacing prior $400M program.

## SEC filing metadata
- accession: 0000950170-25-103543
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000095017025103543/0000950170-25-103543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000095017025103543/lnth-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103543
- JSON: https://secwatch.observer/filing/0000950170-25-103543.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.